Literature DB >> 6298550

Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesions.

R S Chang, V J Lotti, G E Martin, T B Chen.   

Abstract

Specific 125I-CCK receptor binding was significantly increased in brain tissue taken from guinea pig or mouse following chronic (2-3 week) daily administration of haloperidol (2-3 mg/kg/day). Scatchard analysis indicated the increase in CCK binding was due to an increased receptor number (B max) with no change in affinity (Kd). In guinea pigs, the increased CCK binding was observed in the mesolimbic regions and frontal cortex, but not in striatum, hippocampus nor posterior cortex. In mice, however, the increases occurred in both pooled cerebral cortical-hippocampal tissue, and in the remainder of the brain. Enhanced CCK receptor binding was also observed in membranes prepared from whole brain of mice one month following intracisternal injection of 6-hydroxydopamine. Additionally, an increase in CCK binding was observed in mesolimbic regions and frontal cortex, but not striatum or hippocampus, of guinea pigs 3 weeks after an unilateral radiofrequency lesions of the ipsilateral ventral tegmentum. The present studies demonstrate that three different procedures which reduce dopaminergic function in the brain enhance CCK receptor binding. The data provide further support for a functional interrelationship between dopaminergic systems and CCK in some brain regions and raise the possibility that CCK may play a role in the antipsychotic action of neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6298550     DOI: 10.1016/0024-3205(83)90224-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.

Authors:  F Weiss; A Ettenberg; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Authors:  R S Chang; V J Lotti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

3.  Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.

Authors:  A J Stoessl; C T Dourish; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.

Authors:  Y Hama; M Ebadi
Journal:  Neurochem Res       Date:  1987-08       Impact factor: 3.996

5.  Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.

Authors:  J A Severson; H E Robinson; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

7.  Cholecystokinin binding sites in the rat forebrain: effects of acute and chronic methamphetamine administration.

Authors:  T Suzuki; T Moroji
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.